Trial Profile
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary) ; Tocilizumab (Primary) ; Diphenhydramine; Leflunomide; Methotrexate; Methylprednisolone; Paracetamol
- Indications Rheumatoid arthritis
- Focus Biomarker; Therapeutic Use
- Acronyms BIOBIO
- 18 Nov 2021 Results (n=95) assessing Torque Teno Virus development over time due to heterogeneity for monitoring of immunomodulation with biological compounds in the treatment of rheumatoid arthritis, published in the Rheumatology
- 30 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2018 This trial has been completed in Austria.